Lino-M 850


Lino-M 850


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)



Linagliptin + Metformin Hydrochloride



This can be shown as an aide to eat less and work out to move forward glycemic control in grown-ups with sort 2 diabetes mellitus when treatment with both Linagliptin and Metformin Hydrochloride is suitable



Linagliptin is indicated to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta (β) cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha (α) cells in the circulation.

Metformin Hydrochloride may be a biguanide sort verbal antihyperglycemic medicate utilized within the administration of sort 2 diabetes. It brings down both basal and postprandial plasma glucose. Its component of activity is distinctive from those of sulfonylureas and it does not deliver hypoglycemia. Metformin Hydrochloride diminishes hepatic glucose generation, diminishes intestinal retention of glucose and makes strides affront affectability by an increment in fringe glucose take-up and utilization.


Dosage and Administration

Linagliptin & Metformin quick discharge tablet: The dose of Linagliptin & Metformin ought to be individualized on the premise of both adequacy and tolerability. Greatest prescribed dosage of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice day by day with suppers.
Dosage heightening ought to be progressive to decrease the gastrointestinal (GI) side impacts related with Metformin Hydrochloride utilize.
Suggested beginning dosage: In patients right now not treated with Metformin Hydrochloride, start treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.
In patients as of now treated with Metformin Hydrochloride, begin with 2.5 mg Linagliptin and the current dosage of Metformin Hydrochloride twice daily.

Patients as of now treated with Linagliptin and Metformin Hydrochloride, person components may be exchanged to this combination containing the same dosages of each component.
Linagliptin & Metformin amplify discharge tablet: The dose of this combination ought to be individualized on the premise of both viability and tolerability, whereas not surpassing the greatest suggested add up to day by day measurements of Linagliptin 5 mg and Metformin Hydrochloride 2000 mg. this combination ought to be given once day by day with a meal.
Recommended beginning measurements: In patients right now not treated with metformin, start this combination treatment with 5 mg Linagliptin/1000 mg Metformin Hydrochloride extended-release once every day with a dinner.
In patients as of now treated with Metformin, begin this combination with 5 mg of Linagliptin add up to day by day dosage and a comparable add up to every day measurements of Metformin once every day with a meal.
In patients as of now treated with Linagliptin & Metformin prompt discharge tablet, switch to expand discharge tablet containing 5 mg of Linagliptin add up to every day measurements and a comparable add up to day by day measurements of Metformin once day by day with a meal.
5 mg Linagliptin & 1000 mg Metformin Hydrochloride extended-release tablet ought to be taken as a single tablet once every day. Patients utilizing 2.5 mg Linagliptin & 1000 mg Metformin amplified discharge tablets ought to take two tablets together once every day.


Cationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May diminish metformin elimination.

P-glycoprotien/CYP3A4 inducer (i.e. rifampin): The adequacy of this pharmaceutical may be diminished when managed in combination.



In spite of the fact that Linagliptin experiences negligible renal excretion, Metformin Hydrochloride is known to be significantly excreted by the kidney. The hazard of Metformin Hydrochloride aggregation and lactic acidosis increments with the degree of renal impedance. Hence, this combination is contraindicated in patients with renal impedance. It is additionally contraindicated in intense or persistent metabolic acidosis (diabetic ketoacidosis) and in extreme touchiness to Linagliptin or Metformin Hydrochloride.


Side Effects

Most common side impacts are nasopharyngitis and the runs. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.


Pregnancy & Lactation

There are no satisfactory and well-controlled thinks about in pregnant ladies with this combination or its person component; so it ought to be utilized amid pregnancy as it were in case clearly required. Caution ought to too be excercised when it is managed to a lactating mother.


Precautions & Warnings

In a quiet with lactic acidosis who is taking Metformin, the medicate ought to be suspended instantly and steady treatment instantly organizations. There have been postmarketing reports of intense pancreatitis. On the off chance that pancreatitis is suspected, instantly cease Linagliptin & Metformin. Briefly suspend Linagliptin & Metformin in patients experiencing radiologic thinks about with intravascular organization of iodinated differentiate materials or any surgical methods requiring limited admissions of nourishment and liquids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be observed yearly.


Therapeutic Class

Combination Oral hypoglycemic preparations


Storage Conditions

Keep in a cool & dry put (underneath 30°C), ensured from light & dampness. Keep out of the reach of children.


Pharmaceutical Name

Acme Laboratories Ltd.